CN113382727A - 与引起酸中毒的药物联合给药的药物组合物 - Google Patents
与引起酸中毒的药物联合给药的药物组合物 Download PDFInfo
- Publication number
- CN113382727A CN113382727A CN201980090677.XA CN201980090677A CN113382727A CN 113382727 A CN113382727 A CN 113382727A CN 201980090677 A CN201980090677 A CN 201980090677A CN 113382727 A CN113382727 A CN 113382727A
- Authority
- CN
- China
- Prior art keywords
- acidosis
- acid
- causing
- composition
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010444 Acidosis Diseases 0.000 title claims abstract description 94
- 208000026545 acidosis disease Diseases 0.000 title claims abstract description 90
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 229940079593 drug Drugs 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 230000007950 acidosis Effects 0.000 claims abstract description 76
- 230000000694 effects Effects 0.000 claims abstract description 38
- 239000002253 acid Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 46
- YYOOFJZTRCPVFD-UHFFFAOYSA-N 3-[[3-[4-(methanesulfonamido)phenyl]-4-oxochromen-7-yl]oxymethyl]benzoic acid Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1=COC2=CC(OCC=3C=C(C=CC=3)C(O)=O)=CC=C2C1=O YYOOFJZTRCPVFD-UHFFFAOYSA-N 0.000 claims description 24
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 claims description 20
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 20
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims description 20
- FLCWJWNCSHIREG-UHFFFAOYSA-N 2-(diethylamino)benzaldehyde Chemical compound CCN(CC)C1=CC=CC=C1C=O FLCWJWNCSHIREG-UHFFFAOYSA-N 0.000 claims description 18
- 208000030507 AIDS Diseases 0.000 claims description 18
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 18
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 16
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 16
- 229960003105 metformin Drugs 0.000 claims description 14
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229960003907 linezolid Drugs 0.000 claims description 13
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 13
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 12
- 229940093265 berberine Drugs 0.000 claims description 12
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 12
- 229960003243 phenformin Drugs 0.000 claims description 12
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 229960003350 isoniazid Drugs 0.000 claims description 11
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 11
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 claims description 10
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 229960002563 disulfiram Drugs 0.000 claims description 10
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 208000007345 glycogen storage disease Diseases 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 208000017169 kidney disease Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 208000019423 liver disease Diseases 0.000 claims description 9
- 208000012268 mitochondrial disease Diseases 0.000 claims description 9
- 201000006938 muscular dystrophy Diseases 0.000 claims description 9
- 231100000572 poisoning Toxicity 0.000 claims description 9
- 230000000607 poisoning effect Effects 0.000 claims description 9
- 208000020016 psychiatric disease Diseases 0.000 claims description 9
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 8
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 8
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 8
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 8
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 8
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 8
- 208000016285 Movement disease Diseases 0.000 claims description 8
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 8
- GWYBSWWLKXEDLB-UHFFFAOYSA-N [acetyl-(4-chlorophenyl)sulfonylamino] acetate Chemical compound CC(=O)ON(C(C)=O)S(=O)(=O)C1=CC=C(Cl)C=C1 GWYBSWWLKXEDLB-UHFFFAOYSA-N 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- UMWYYMCOBYVEPY-UHFFFAOYSA-N azanide;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2] UMWYYMCOBYVEPY-UHFFFAOYSA-N 0.000 claims description 8
- 229960001761 chlorpropamide Drugs 0.000 claims description 8
- 229940043350 citral Drugs 0.000 claims description 8
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 8
- 150000002085 enols Chemical class 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 8
- 229930000755 gossypol Natural products 0.000 claims description 8
- 229950005277 gossypol Drugs 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 229930002330 retinoic acid Natural products 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- OOLBCHYXZDXLDS-UHFFFAOYSA-N 2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CC=C(Cl)C=C1Cl OOLBCHYXZDXLDS-UHFFFAOYSA-N 0.000 claims description 6
- BLKAHDBNTYNLJN-UHFFFAOYSA-N 2-oxopropanoic acid;hydrate Chemical compound O.CC(=O)C(O)=O BLKAHDBNTYNLJN-UHFFFAOYSA-N 0.000 claims description 6
- 239000005506 Diclofop Substances 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- IPGOVDXOBDFUBM-UHFFFAOYSA-N oxalic acid;sodium Chemical compound [Na].OC(=O)C(O)=O IPGOVDXOBDFUBM-UHFFFAOYSA-N 0.000 claims description 5
- -1 Phospho Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- XFYIHRTWDXNCTA-UHFFFAOYSA-N Eugenin Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC1CCC2C(C)(CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)CCC34C)C1C XFYIHRTWDXNCTA-UHFFFAOYSA-N 0.000 claims description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims description 2
- SUTUBQHKZRNZRA-UHFFFAOYSA-N eugenin Chemical compound O1C(C)=CC(=O)C=2C1=CC(OC)=CC=2O SUTUBQHKZRNZRA-UHFFFAOYSA-N 0.000 claims description 2
- DEDOPGXGGQYYMW-UHFFFAOYSA-N molinate Chemical compound CCSC(=O)N1CCCCCC1 DEDOPGXGGQYYMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001779 pargyline Drugs 0.000 claims description 2
- NWGYTLGTDHTPQB-UHFFFAOYSA-M sodium 2-oxopropanoate hydrate Chemical compound O.[Na+].CC(=O)C([O-])=O NWGYTLGTDHTPQB-UHFFFAOYSA-M 0.000 claims description 2
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 claims description 2
- 229940039790 sodium oxalate Drugs 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 230000036541 health Effects 0.000 abstract description 7
- 238000011260 co-administration Methods 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 38
- 239000000126 substance Substances 0.000 description 37
- 208000006443 lactic acidosis Diseases 0.000 description 25
- 239000004310 lactic acid Substances 0.000 description 19
- 235000014655 lactic acid Nutrition 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 206010027417 Metabolic acidosis Diseases 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000003826 Respiratory Acidosis Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000000122 hyperventilation Diseases 0.000 description 3
- 230000000870 hyperventilation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940097693 Aldehyde dehydrogenase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及与引起酸中毒的药物联合给药的药物组合物。酸中毒是由于体内产生大量酸蓄积而引起的酸碱平衡紊乱。在许多情况下,酸中毒作为与治疗各种疾病的药物相关的副作用而发生,这带来了问题。本发明的药物组合物不仅可以维持与导致酸中毒的药物联合给药目的,而且在降低由于酸中毒的药物给药而在生物体内积累的酸浓度方面具有显著效果。因此,所述药物组合物有望广泛应用于医学和健康领域。
Description
技术领域
本发明涉及与引起酸中毒的药物联合给药的药物组合物。
背景技术
酸中毒是指pH值低于正常动脉血pH值7.4±0.05的状态(即氢离子浓度高的状态)。酸中毒分为“呼吸性酸中毒”和“代谢性酸中毒”,代谢性酸中毒的种类包括糖尿病酮症酸中毒、乳酸性酸中毒或水杨酸、甲醇、乙二醇等有毒物质中毒。其中,乳酸性酸中毒是指在体内产生大量乳酸并蓄积的情况下,由于酸碱平衡被破坏而发生的酸中毒,定义为乳酸超过45mg/dL。在细胞中,葡萄糖在氧气存在下被代谢以产生能量。然而,在没有氧气的情况下代谢葡萄糖,会产生乳酸。如果乳酸性酸中毒持续,酸碱平衡被破坏,可能会出现肌肉无力、过度换气、恶心、呕吐、出汗或昏迷等症状,这些症状严重时可能导致死亡。因此,通过降低体内过度积累的乳酸浓度来维持酸碱平衡很重要。然而,在许多情况下,乳酸性酸中毒作为与治疗各种疾病的药物相关的副作用而发生。例如,降糖药二甲双胍是非常有效的降糖药;然而,众所周知,二甲双胍最重要的副作用是胃肠功能下降和乳酸性酸中毒。
因此,本发明是为了解决现有技术中的上述问题而做出的,并且本发明涉及一种用于与引起酸中毒的药物联合给药的药物组合物。本发明的药物组合物不仅可以维持与导致酸中毒的药物联合给药目的,而且在降低由于酸中毒的药物给药而在生物体内积累的酸浓度方面具有显著效果。因此,所述药物组合物有望广泛应用于医学和健康领域。
技术问题
本发明是为了解决现有技术中的上述问题而做出的,并且涉及一种用于与引起酸中毒的药物联合给药的药物组合物。
然而,本发明所要解决的技术问题不限于上述问题,本领域普通技术人员通过以下描述将清楚地理解未提及的其他问题。
解决问题方案
在下文中,参考附图来描述本文描述的各种实施例。在以下描述中,阐述了许多具体细节,例如具体配置、组成和工艺等,以提供对本发明的透彻理解。然而,某些实施例可以在没有这些特定细节中的一个或多个的情况下实施,或者与其他已知方法和配置结合实施。在其他情况下,为了避免不必要地混淆本发明,没有特别详细地描述众所周知的工艺和制备技术。在整个说明书中对“一个实施例”或“一实施例”的引用意味着结合该实施例描述的特定特征、配置、组成或特性包括在本发明的至少一个实施例中。因此,在本说明书的各个地方出现的短语“在一个实施例中”或“一个实施例”不一定指代本发明的相同实施例。此外,在一个或多个实施例中,特定特征、配置、组成或特性可以以任何合适的方式组合。
除非在说明书中另有定义,否则本文所用的所有科学和技术术语应具有与本发明所属领域的普通技术人员通常所理解的相同的含义。
在本发明的一个实施方案中,术语“酸中毒”是指pH低于7.4±0.05的正常动脉pH的状态(即,氢离子浓度高的状态)。根据病因不同,酸中毒分为“呼吸性酸中毒”,即肺部吸氧不足或血流量减少导致组织供氧减少;和“代谢性酸中毒”,其中血液或局部组织中的乳酸量增加,而不管氧气水平的降低。呼吸性酸中毒的原因包括出血休克、心脏病发作、充血性心力衰竭、肺水肿、严重贫血等。代谢性酸中毒是由以下三种机制中的一种或多种引起的:酸负荷、碱丢失或肾酸排泄受损。酸增加的情况的例子包括糖尿病酮症酸中毒、乳酸性酸中毒或有毒物质如水杨酸、甲醇和乙二醇中毒。
在本发明的一个实施方案中,术语“乳酸性酸中毒”是酸中毒的一种,是指在体内产生和积累大量乳酸的情况下,由于酸碱平衡被破坏而发生的酸中毒,并被定义为乳酸超过45mg/dL且pH值为7.45或更低的状态。在细胞中,葡萄糖在氧气存在下被代谢以产生能量。然而,葡萄糖在没有氧气的情况下代谢会产生乳酸。如果乳酸性酸中毒持续,酸碱平衡被破坏,可能会出现肌肉无力、过度换气、恶心、呕吐、出汗或昏迷等症状,这些症状严重时可能导致死亡。因此,通过降低体内过度积累的乳酸浓度来维持酸碱平衡很重要。乳酸性酸中毒的原因包括肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、药物和毒物、严重感染(全身性败血症和脑膜炎)、肿瘤、几种影响正常ATP产生的遗传性代谢和线粒体疾病和肌肉萎缩症,以及剧烈运动。
在本发明的一个实施方案中,术语“引起乳酸性酸中毒的药物”是指在体内引起乳酸性酸中毒作为其给药目以外的副作用的药物。例如,二甲双胍,其是一种抗糖尿病药物,具有非常有效的糖尿病治疗效果,会导致胃肠功能下降和乳酸性酸中毒副作用。从上述药物引起的乳酸性酸中毒导致药物难以自由使用的来看,这对健康/制药行业造成了巨大的损失。因此,需要开发在与引起乳酸性酸中毒的药物联合给药的情况下能够抑制乳酸性酸中毒副作用的药物。
在本发明的一个实施方案中,术语“治疗”是指为减轻和/或改善目标疾病而实施的行为。为了本发明的目的,治疗包括消除由施用引起酸中毒的药物引起的酸中毒的原因;或在无法消除原因的情况下,通过降低产生的酸的浓度来改善酸中毒症状的行为。
在本发明的一个实施方案中,术语“药物组合物”是指为了特定目的而施用的组合物。出于本发明的目的,本发明的药物组合物旨在预防或治疗由给药引起酸中毒的药物引起的酸中毒,并且可以包含涉及这种预防或治疗的化合物以及药学上可接受的载体、赋形剂或稀释剂。此外,本发明的药物组合物包含占组合物总重量0.1%至50%重量的本发明活性成分。可包含在本发明组合物中的载体、赋形剂和稀释剂的实例可包括但不限于乳糖、右旋糖、蔗糖、山梨糖醇、甘露糖醇、木糖醇、赤藓糖醇、麦芽糖醇、淀粉、阿拉伯树胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酸镁和矿物油。
在本发明的一个实施方案中,术语“给药”是指通过任何合适的方式将本发明的组合物给予患者,并且本发明的组合物可以通过任何常用途径给药,只要该途径允许成分到达靶组织。可提及口服给药、腹腔给药、静脉内给药、肌肉给药、皮下给药、皮内给药、鼻内给药、肺内给药、直肠给药、腔内给药、腹腔内给药和鞘内给药;然而,本发明不限于此。在本发明中,有效量可以根据多种因素进行调整,包括疾病的类型、疾病的严重程度、组合物中所含活性成分和其他成分的类型和含量、制剂类型、患者的年龄、体重、一般健康状况、性别和饮食、给药频率、给药途径、组合物的分泌速率、治疗持续时间和同时使用的药物。对于成人,治疗药物组合物可以一次50ml至500ml的量施用于身体,其中在活性成分是化合物的情况下,剂量可以是0.1ng/kg至10mg/kg。在活性成分是单克隆抗体的情况下可以是0.1ng/kg至10mg/kg。每天给药1~12次;一天12次的,可以每2小时给药一次。此外,本发明的药物组合物可以单独给药或与本领域已知的其他疗法如化学疗法、放射疗法和手术联合给药,用于治疗靶癌干细胞。此外,本发明的药物组合物可以与设计用于增强免疫反应的其他治疗联合给药,例如本领域众所周知的佐剂或细胞因子(或编码细胞因子的核酸)。也可以使用其他标准递送方法,例如基因枪转移或离体治疗。在离体治疗中,例如,抗原呈递细胞(APC)、树突细胞、外周血单核细胞或骨髓细胞可以从患者或合适的供体获得并用本药物组合物离体活化,然后回到病人身边。
在本发明的一个实施方案中,“食物组合物”以各种方式用于预防或改善本发明所针对的适应症。包含本发明的组合物作为活性成分的食品组合物可以以各种食品的形式制备,例如饮料、口香糖、茶、维生素复合物、粉剂、颗粒剂、片剂、胶囊、糖果、年糕、面包之类的。本发明的食品组合物由对现有的毒性和副作用小的食品成分进行改良而得到的成分组分,因此在长期摄取的情况下可以放心地用于预防目的。在本发明的组合物包含在食品组合物中的情况下,本发明的组合物可以以相当于总重量的0.1%至100%的比例的量添加。在此,在以饮料的形式制备食品组合物的情况下,除了饮料包含指定比例的食品组合物之外没有特别限制,并且饮料可以含有各种调味剂或天然碳水化合物,或者与传统饮料类似的附加成分。即,天然碳水化合物的实例可包括单糖如葡萄糖、二糖如果糖、多糖如蔗糖、常规糖如糊精和环糊精,以及糖醇如木糖醇、山梨糖醇和赤藓糖醇。调味剂的实例可包括天然调味剂(奇异果甜蛋白、甜菊提取物(例如莱鲍迪甙A、甘草甜素等)和合成调味剂(糖精、阿斯巴甜等)。此外,本发明的食品组合物可以含有各种营养素、维生素、矿物质(电解质)、调味剂(例如合成调味剂和天然调味剂)、着色剂、果胶酸及其盐、藻酸及其盐、有机酸、保护胶体、增稠剂、pH调节剂、稳定剂、防腐剂、甘油、酒精、碳酸饮料中使用的碳化剂等。这些成分可以单独使用或组合使用。这些添加剂的比例通常在每100重量份本发明组合物中以0.1至100重量份范围内选择;然而,本发明不限于此。
在本发明的一个实施方案中,提供了一种与引起酸中毒的药物联合给药的药物组合物,该组合物包含醛脱氢酶作为活性成分。在所述药物组合物中,所述醛脱氢酶可以为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸(3-hydroxy-DL-kynurenine)、苯菌灵(benomyl)、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸(kynurenicacid)、禾草特(molinate)、优降宁(pargyline)、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛(phenylglyoxal)、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。在药物组合物中,引起酸中毒的药物可为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良症、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。在所述药物组合物中,引起酸中毒的药物可以为选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。在药物组合物中,酸中毒可以是动脉血pH为7.35或更低的病症。
在本发明的另一实施方案中,提供了与引起酸中毒的药物联合给药的食品组合物,其包含醛脱氢酶作为活性成分。在所述食品组合物中,所述醛脱氢酶可以为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。在食品组合物中,引起酸中毒的药物可以为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良症、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。在食品组合物中,引起酸中毒的药物可以是选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。在食品组合物中,酸中毒可以是动脉血pH为7.35或更低的病症。
在本发明的另一实施方案中,提供了一种预防或治疗由引起酸中毒的药物引起的酸中毒副作用的方法,包括向有需要的受试者施用包含醛脱氢酶作为活性成分的组合物。在该方法中,醛脱氢酶可以是选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠中的中的至少任意一种。在该方法中,引起酸中毒的药物可以为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。该方法中,引起酸中毒的药物可以是选自下组的至少任意一种:选自二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺中的至少一种。在该方法中,酸中毒可以是动脉血pH为7.35或更低的病症。
在本发明的另一实施方案中,提供了一种用于预防或治疗由引起酸中毒的药物引起的酸中毒副作用的组合物,该组合物包含醛脱氢酶作为活性成分。在所述组合物中,所述醛脱氢酶可以为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。在该组合物中,引起酸中毒的药物可以为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。在该组合物中,引起酸中毒的药物可以是选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。在组合物中,酸中毒可以是动脉血pH为7.35或更低的病症。
在下文中,将逐步详细地描述本发明。
发明的有益效果
本发明涉及一种用于预防或治疗酸中毒的药物组合物。本发明的药物组合物不仅可以维持与导致酸中毒的药物联合给药目的,而且在降低由于酸中毒的药物给药而在生物体内积累的酸浓度方面具有显著效果。因此,所述药物组合物有望广泛应用于医学和健康领域。
附图简要简述
图1说明了根据本发明的一个实施方案,通过使用A549细胞鉴定与引起酸中毒的二甲双胍组合施用治疗酸中毒的候选物质的效果。
图2说明了根据本发明的一个实施方案,通过使用A549细胞鉴定与引起酸中毒的异烟肼组合施用治疗酸中毒的候选物质的效果。
图3A和3B示出了根据本发明的一个实施方案,通过使用A549细胞鉴定与引起酸中毒的小檗碱组合施用治疗酸中毒的候选物质的效果。
图4A和4B示出了根据本发明的一个实施方案,通过使用L132细胞鉴定与引起酸中毒的小檗碱组合施用治疗酸中毒的候选物质的效果。
图5A和5B示出了根据本发明的一个实施方案,通过使用A549细胞鉴定与引起酸中毒的利奈唑胺组合施用治疗酸中毒的候选物质的效果。
图6A和6B示出了根据本发明的一个实施方案,通过使用L132细胞鉴定与引起酸中毒的利奈唑胺组合施用治疗酸中毒的候选物质的效果。
图7A和7B示出了根据本发明的一个实施方案,通过使用A549细胞鉴定与引起酸中毒的苯乙双胍组合施用治疗酸中毒的候选物质的效果。
图8A和8B示出了根据本发明的一个实施方案,通过使用L132细胞鉴定与引起酸中毒的苯乙双胍组合施用治疗酸中毒的候选物质的效果。
发明详述
本发明人筛选了醛脱氢酶抑制剂(ALDH抑制剂)的各种候选物质以开发用于治疗酸中毒的物质,并确定了候选物质与已知乳酸性酸中毒作为副作用(不是预期的药物用途)的药物联合给药的效果。结果发现,即使对于用于治疗酸中毒的候选物质,在单独给药的情况下具有相似的降低乳酸浓度的效果,这些候选物质在与引起乳酸的物质联合给药的情况下表现出非常不同的效果,并且效果也取决于引起乳酸性酸中毒的物质类型。
在下文中,将通过实施例更详细地描述本发明。这些实施例仅用于更详细地描述本发明,对于本领域技术人员来说显而易见的是,根据本发明的要旨,本发明的范围不受这些实施例的限制。
实施例1:筛选用于酸中毒治疗的候选物质
本发明人通过筛选各种醛脱氢酶抑制剂(ALDH抑制剂)的候选物质以开发治疗酸中毒的物质,结果发现如下表1所示的物质。
表1
实施例2:测定酸中毒治疗候选物质与引起酸中毒的物质联合给药的效果
使用以下物质作为引起乳酸性酸中毒的物质:二甲双胍或苯乙双胍作为双胍类抗糖尿病药物;异烟肼作为抗结核药或抗抑郁药;小檗碱作为抗病毒剂、抗真菌剂或抗生素;或利奈唑胺作为恶唑烷酮类抗生素。这些药物是已知乳酸性酸中毒作为其预期药物用途以外的副作用的药物。
为了鉴定实施例1所述的治疗乳酸性酸中毒的候选物质与上述引起乳酸性酸中毒的物质联合给药的效果,将A549细胞(癌细胞)或L132细胞(正常细胞)分别接种于96-或24孔板,浓度为1×104或3×105个细胞/孔,孵育过夜。进行酸中毒治疗候选物质与引起乳酸性酸中毒的物质的联合给药,并进一步进行24小时孵育。对于酸中毒治疗的候选物质,每种物质均以50μM的均匀浓度给药;对于引起乳酸性酸中毒的物质,给药浓度如下:二甲双胍为1~100μM,异烟肼为1~500μM,小檗碱为10μM,利奈唑胺为200μM,苯乙双胍为100μM。将所有物质溶解在二甲亚砜(DMSO,西格玛-阿拉丁,圣路易斯,MO,美国)中,且联合给药的物质同时给药。随后,将50μl用杜尔贝科的磷酸缓冲盐(DPBS;威健,韩国)稀释得到的细胞培养液和50μl乳酸检测反应缓冲液(普罗美加,麦迪逊,WI,美国)混合,混合物加入96孔板中。使反应在室温下进行1小时。然后,用分光光度计(SynergyHTX多读卡器;生物科技威努斯基,佛蒙特州,美国)测量发光。同时,用细胞活力分析试剂盒(细胞计数试剂盒-8;同仁堂分子技术公司,熊本,日本)测定每个样品中的细胞数,并进行计算,以便可以将每个样品的乳酸测量值与相同细胞数的阴性对照中的乳酸测量值进行比较。实验结果示于图1-8以及下表2-7。
表2
表3
表4
表5
表6
表7
由以上结果可知,即使对于用于治疗酸中毒的候选物质,在单独给药的情况下具有相似的降低乳酸浓度的效果,这些候选物质在与引起乳酸性酸中毒的物质联合给药的情况下表现出非常不同的效果,并且效果也取决于引起乳酸性酸中毒的物质类型。例如,在将作为酸中毒治疗候选物质的DEAB或双硫仑单独给予L132细胞的情况下,与阴性对照组相比,这些物质分别显示相似的乳酸水平,分别为93.41±2.71和93.39±2.64。而在将DEAB或双硫仑与利奈唑胺联合给药于L132细胞的情况下,这些物质显示出显著不同的乳酸水平下降率,与阳性对照组相比,分别对应于增加5.21%和减少12.84%。
虽然已经对本发明的具体部分进行了详细的描述,但是对于本领域技术人员来说,这样的具体描述只是一个优选实施例是显而易见的,本发明的范围并不限于此。因此,本发明的实质范围将由所附权利要求及其等同物来限定。
工业适用性
乳酸性酸中毒是指在体内产生大量乳酸并蓄积的情况下,由于酸碱平衡被破坏而发生的酸中毒。如果乳酸性酸中毒持续,酸碱平衡被破坏,可能会出现肌肉无力、过度换气、恶心、呕吐、出汗或昏迷等症状,这些症状严重时可能导致死亡。因此,通过降低体内过度积累的乳酸浓度来维持酸碱平衡很重要。然而,在许多情况下,乳酸性酸中毒作为与治疗各种疾病的药物相关的副作用而发生。本发明的药物组合物不仅可以维持与导致酸中毒的药物联合给药目的,而且在降低由于酸中毒的药物给药而在生物体内积累的酸浓度方面具有显著效果。因此,所述药物组合物有望广泛应用于医学和健康领域。
本发明的药物组合物不仅可以维持导致酸中毒的药物的给药目的,而且在降低由于给药导致酸中毒的药物而在生物体内积累的酸浓度方面具有显著效果。导致酸中毒。因此,该药物组合物有望广泛应用于医学和健康领域。
Claims (20)
1.一种与引起酸中毒的药物联合给药的药物组合物,所述组合物包含醛脱氢酶作为活性成分。
2.根据权利要求1的药物组合物,其特征在于,所述醛脱氢酶为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸(3-hydroxy-DL-kynurenine)、苯菌灵(benomyl)、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸(kynurenicacid)、禾草特(molinate)、优降宁(pargyline)、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛(phenylglyoxal)、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。
3.根据权利要求1所述的药物组合物,其特征在于,所述引起酸中毒的药物为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良症、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。
4.根据权利要求3的药物组合物,其特征在于,所述引起酸中毒的药物为选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。
5.根据权利要求1所述的药物组合物,其特征在于,酸中毒是动脉血pH为7.35或更低的病症。
6.一种与引起酸中毒的药物联合给药的食品组合物,所述组合物包含醛脱氢酶作为活性成分。
7.根据权利要求6所述的食品组合物,其特征在于,所述醛脱氢酶为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。
8.根据权利要求6所述的食品组合物,其特征在于,所述引起酸中毒的药物为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良症、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。
9.根据权利要求8所述的食品组合物,其特征在于,所述引起酸中毒的药物为选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。
10.根据权利要求6所述的食物组合物,其特征在于,酸中毒是动脉血pH为7.35或更低的病症。
11.一种预防或治疗由引起酸中毒的药物引起的酸中毒副作用的方法,包括向有需要的受试者施用包含醛脱氢酶作为活性成分的组合物。
12.根据权利要求11所述的方法,其特征在于,所述醛脱氢酶为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。
13.根据权利要求11所述的方法,其特征在于,所述引起酸中毒的药物为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。
14.根据权利要求13所述的方法,其特征在于,引起酸中毒的药物为选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。
15.根据权利要求11的方法,其特征在于,酸中毒是动脉血pH为7.35或更低的病症。
16.一种用于预防或治疗由引起酸中毒的药物引起的酸中毒副作用的组合物,所述组合物包含醛脱氢酶作为活性成分。
17.根据权利要求16所述的组合物,其特征在于,所述醛脱氢酶为选自下组的至少任意一种:3-羟基-DL-犬尿氨酸、苯菌灵、顺式二氨基二氯铂(CDDP)、氯丙酰胺、柠檬醛、CVT-10216(3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-1-苯并吡喃-7-基]氧基]甲基]苯甲酸、或3-[[[3-[4-[(甲磺酰基)氨基]苯基]-4-氧代-4H-色烯-7-基]氧基]甲基]苯甲酸)、氰胺、黄豆苷、二乙氨基苯甲醛(DEAB)、双硫仑、棉酚、犬尿喹啉酸、禾草特、优降宁、磷酸(烯醇)丙酮酸单钠盐水合物、苯甲酰甲醛、视黄酸、N-乙酰基-N-乙酰氧基-4-氯苯磺酰胺和草酸钠。
18.根据权利要求16所述的组合物,其特征在于,所述引起酸中毒的药物为用于治疗肝病、肾病、神经系统疾病、精神障碍、糖尿病、白血病、获得性免疫缺陷综合征(AIDS)、糖原贮积病、感染、肿瘤、肌营养不良、遗传代谢紊乱、线粒体紊乱、急性运动障碍或毒素中毒。
19.根据权利要求18所述的组合物,其特征在于,所述引起酸中毒的药物选自下组的至少任意一种:二甲双胍、苯乙双胍、异烟肼、小檗碱和利奈唑胺。
20.根据权利要求16所述的组合物,其特征在于,酸中毒是动脉血pH为7.35或更低的病症。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0151783 | 2018-11-30 | ||
KR20180151783 | 2018-11-30 | ||
KR1020190155223A KR20200066213A (ko) | 2018-11-30 | 2019-11-28 | 산증 유발 약제의 병용 투여용 약학조성물 |
KR10-2019-0155223 | 2019-11-28 | ||
PCT/KR2019/016729 WO2020111869A1 (ko) | 2018-11-30 | 2019-11-29 | 산증 유발 약제의 병용 투여용 약학조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113382727A true CN113382727A (zh) | 2021-09-10 |
Family
ID=71082109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980090677.XA Pending CN113382727A (zh) | 2018-11-30 | 2019-11-29 | 与引起酸中毒的药物联合给药的药物组合物 |
Country Status (2)
Country | Link |
---|---|
KR (2) | KR20200066213A (zh) |
CN (1) | CN113382727A (zh) |
-
2019
- 2019-11-28 KR KR1020190155223A patent/KR20200066213A/ko not_active Application Discontinuation
- 2019-11-29 CN CN201980090677.XA patent/CN113382727A/zh active Pending
-
2021
- 2021-08-09 KR KR1020210104440A patent/KR20210101186A/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20210101186A (ko) | 2021-08-18 |
KR20200066213A (ko) | 2020-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201836596A (zh) | 伽瑪(γ)-羥基丁酸鹽組合物及其用於治療病症之用途 | |
US8829057B2 (en) | AMPK activating agent | |
US11938123B2 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
EP3132798B1 (en) | Use of composition containing iron (ii) amino acid chelate in preparing drug for regulating and controlling fat metabolism | |
US20100210589A1 (en) | Method for improving hepatic function | |
KR102011815B1 (ko) | 산증의 예방 또는 치료용 약학조성물 | |
US20220125745A1 (en) | Pharmaceutical composition for co-administration of acidosis-inducing drug | |
CN111388462B (zh) | 一种具有降血糖作用的组合物及应用 | |
JP5063369B2 (ja) | メグリチニド類を含有する肝臓線維化予防用医薬組成物 | |
US9018176B2 (en) | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | |
CN113382727A (zh) | 与引起酸中毒的药物联合给药的药物组合物 | |
Širvinskas et al. | Perioperative use of metformin in cardiac surgery | |
KR102209386B1 (ko) | 호모해링토닌을 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학조성물 | |
CN113543777A (zh) | 用于预防或治疗酸中毒的药物组合物 | |
Fraser et al. | Ranitidine has no effect on postbreakfast ethanol absorption. | |
KR102088689B1 (ko) | 산증의 예방 또는 치료용 약학조성물 | |
CN110384692B (zh) | 鼠尾草酸和迷迭香酸联合制备防治ⅱ型糖尿病肾病的药物的用途 | |
EP3804705B1 (en) | Pharmaceutical composition for preventing diabetes and use thereof | |
US20230270733A1 (en) | Preventive, relief or therapeutic use of 2,3,5-substituted thiophene compound against gastrointestinal stromal tumor | |
CN103355665B (zh) | 一种用于辅助降血糖的组合物 | |
US11452754B2 (en) | Pharmaceutical composition and uses thereof | |
US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin | |
JP7407298B2 (ja) | 2,3,5-置換されたチオフェン化合物の卵巣癌の予防、改善または治療用途 | |
WO2022061962A1 (zh) | 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法 | |
US11318153B2 (en) | Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210910 |
|
WD01 | Invention patent application deemed withdrawn after publication |